Related Experiment Video
Updated: Jun 5, 2026
05:36
Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Update on iron chelators in thalassemia
1Children's Hospital Boston, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA. ellis.neufeld@chboston.org
Hematology. American Society of Hematology. Education Program
|January 18, 2011
Summary
Iron chelator therapy has greatly improved survival for thalassemia major patients. Recent research clarifies the applications and limitations of different iron chelators, guiding future treatment strategies.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Thalassemia major survival has significantly improved over 40 years.
- This improvement is largely attributed to advancements in iron chelator therapy.
- Key iron chelators include deferoxamine, deferasirox, and deferiprone, with varying global availability.
Purpose of the Study:
- To review recent studies (last 4 years) on iron chelators for thalassemia major.
- To enhance understanding of the applications and limitations of these chelators.
- To identify areas for future research in iron chelation therapy.
Main Methods:
- Review of clinical trials and worldwide clinical experience.
- Analysis of data on iron chelation efficacy, side effects, cost, and adherence.
- Synthesis of information on monotherapy and combination therapy approaches.
Main Results:
- All major iron chelators effectively remove iron and prevent hemosiderosis in thalassemia patients.
- Significant differences exist among chelators regarding side effects, cost, tolerability, and adherence.
- Comparative data across all chelator combinations remain limited.
Conclusions:
- Iron chelators are crucial for managing transfusional iron overload in thalassemia major.
- Patient-specific factors influence the choice of chelator therapy.
- Further head-to-head comparative studies are needed to optimize treatment strategies.
More Related Videos
Related Concept Videos
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
00:56Extraction: Advanced Methods
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is formed in...
01:22EDTA: Chemistry and Properties
Polydentate ligands are most widely used in complexometric titrations because they form more stable complexes with the metal ions than mono- or bidentate ligands due to the chelate effect. Examples of polydentate ligands are ethylenediaminetetraacetic acid (EDTA), crown ethers, and cryptands. The most important feature of optimal polydentate ligands is the ability to form 1:1 complexes in a single-step process. Amino carboxylic acid derivatives are frequently used as complexing agents. EDTA is...
01:17Antidotes
Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...
01:19Complexation Equilibria: The Chelate Effect
In complexation reactions, metal atoms or cations interact with ligands to form donor-acceptor adducts called metal complexes. Ligands that bind through one donor site are monodentate, ligands with two donor sites are bidentate, and those with more than two donor sites are polydentate ligands. For example, ethylene diamine is a bidentate ligand that binds through two nitrogen donor atoms, forming a five-membered ring. EDTA is a polydentate ligand that binds through four oxygen and two nitrogen...
01:26EDTA: Auxiliary Complexing Reagents
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...